|1.||Shelbourne, K Donald: 1 article (12/2015)|
|2.||Benner, Rodney W: 1 article (12/2015)|
|3.||Nixon, Ryan A: 1 article (12/2015)|
|4.||Gray, Tinker: 1 article (12/2015)|
|5.||Xie, Fuqiang: 1 article (01/2015)|
|6.||Zhang, Di: 1 article (01/2015)|
|7.||Lin, Degui: 1 article (01/2015)|
|8.||Huang, Jian: 1 article (01/2015)|
|9.||Dunner, Susana: 1 article (08/2013)|
|10.||Sánchez-Archidona, Ana Rodríguez: 1 article (08/2013)|
07/01/2005 - "In this study, an in vitro multicellular tumor spheroid model was developed using microencapsulation, and the feasibility of using the microencapsulated multicellular tumor spheroid (MMTS) to test the effect of chemotherapeutic drugs was investigated. "
08/01/1996 - "To study the expression of c-erb B-2 in gynecologic malignancies, especially in malignant mixed müllerian tumors (MMTs). "
01/01/2015 - "In MMTs, COX-2 expression correlated with tumor malignancy features. "
05/01/2012 - "To immunohistochemically evaluate matrix metalloproteinase (MMP)-9 expression in benign and malignant mammary gland tumors (MMTs) in dogs and relate expression to prognostic factors and patient outcome. "
04/01/2007 - "Children with EOE were treated either with the strategy used for malignant mesenchymal tumors (MMTs) by the International Society of Pediatric Oncology (SIOP) or with the French Society of Pediatric Oncology (SFOP) regimen used for osseous Ewing tumors (OET). "
|2.||Teratoma (Teratoid Tumor)
05/01/1989 - "In this study 20 solid ovarian teratomas and 15 MMTs of the ovary have been compared according to their clinical, histomorphological, and immunocytochemical characteristics. "
05/01/1989 - "The differential diagnosis between solid teratomas and malignant mixed Müllerian tumors (MMTs) can be difficult, because both tumours have an epithelial as well as a mesenchymal component. "
01/01/2011 - "Bax expression was significantly increased in serous carcinomas as compared to MMTs. "
04/01/2005 - "This indolent behavior of MMTs is similar to that previously reported, but additional cases of invasive carcinomas in this category are needed to better define their outcome."
04/01/2005 - "We analyzed 17 MMTs, including 12 borderline tumors, 2 intraepithelial carcinomas, 2 microinvasive carcinomas, and 1 invasive carcinoma. "
01/01/1997 - "The incidences of hepatocellular adenoma and total liver tumors were significantly smaller in group 3 than those of group 1. The average numbers of hepatocellular adenoma, carcinoma and total tumors in group 3 were significantly smaller than in group 1. Glutathione S-transferase placental form-positive foci were also significantly decreased by MMTS treatment in the promotion phase. "
|5.||Aberrant Crypt Foci
09/15/1995 - "Feeding of 100 ppm MMTS for 5 weeks significantly decreased the number of aberrant crypt foci/colon. "
09/15/1995 - "Feeding of MMTS during the postinitiation phase decreased the number of aberrant crypt foci/colon, colonic ornithine decarboxylase activity, 5-bromodeoxyuridine-labeling index in colonic epithelium, and polyamine level in blood compared with those of AOM alone. "
09/01/1997 - "Regressive effects of four chemopreventive agents [5-hydroxy-4-(2-phenyl-(E)-ethenyl)-2(5H)-furanone (KYN-54), S-methyl methanethiosulfonate (MMTS), chlorogenic acid (CA), and piroxicam] on azoxymethane (AOM)-induced aberrant crypt foci (ACF) in the colon of male F344 rats were examined by dietary exposure. "
|1.||2-methylcyclopentadienyl manganese tricarbonyl (MMT)
|4.||alginic acid (sodium alginate)
|6.||methyl methanethiosulfonate (MMTS)
|9.||Aflatoxin B1 (Aflatoxin B)
|1.||Photochemotherapy (Photodynamic Therapy)
|2.||Euthanasia (Mercy Killing)